Search Prime Grants

R01AI161299

Project Grant

Overview

Grant Description
A Structured Transcriptional Switching Network that Coordinates Antigenic Variation by Malaria Parasites - Project Summary/Abstract

Plasmodium falciparum is the causative agent responsible for the most severe form of human malaria, a disease that kills more than 400,000 people a year, mostly young children in Africa. These protozoan parasites invade and ultimately destroy circulating red blood cells (RBCs) of their host, leading to severe anemia and the frequently lethal syndromes of cerebral malaria and pregnancy-associated malaria.

Over the course of an infection, small sub-populations of parasites arise that have an altered antigenic phenotype, thus avoiding the antibody response of the host. This process is referred to as antigenic variation and is responsible for the persistent nature of the disease as well as the waves of parasitemia frequently observed in P. falciparum infections.

Antigenic variation of P. falciparum infected RBCs results from switches in expression between individual members of the multi-copy var gene family. Each var gene encodes a different form of a protein called PfEMP1. This protein is placed on the infected RBC surface and mediates adhesion to specific receptors found on the endothelial surfaces of the blood vessel walls of the infected individual. This adhesion is responsible for many of the disease manifestations of infection with P. falciparum, including both cerebral malaria and pregnancy-associated malaria.

Only a single var gene is expressed at a time by any given parasite, thus determining both the antigenic phenotype of the infected cells as well as their adhesive properties. Therefore, var gene expression is at the heart of both antigenic variation and virulence of malaria infections.

The long-term objectives of this project are to understand the molecular mechanisms that regulate var gene expression and antigenic variation by malaria parasites. Significant work in recent years has defined many molecular aspects that maintain a gene in the active or silent state; however, the mechanisms governing switching between transcriptionally active genes remain entirely undefined. Moreover, given that an infection can include billions of individual parasites, how they seemingly coordinate switching events to limit activation to a single or small number of genes at a time is completely unexplored. In contrast, uncoordinated, random switching would rapidly exhaust the entire var repertoire. There is no evidence of communication between parasites, and there does not appear to be a strict switching order within the var gene family; therefore, how this is accomplished remains completely mysterious.

The specific aims of the project are designed to decipher the mechanistic basis of this phenomenon. Aim 1 investigates the role of an unusual, highly conserved var gene that appears to function as a central organizing gene that coordinates switching events. Aim 2 will determine how parasites sense the presence of a placenta and alter var gene expression to take advantage of this unusual niche.

This project will contribute to the ongoing effort to disrupt the process of antigenic variation and thereby shorten the length of an infection and reduce its severity.
Funding Goals
NOT APPLICABLE
Place of Performance
New York, New York 100654805 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/26 to 08/31/27 and the total obligations have increased 379% from $703,289 to $3,371,157.
Weill Medical College Of Cornell University was awarded Malaria Parasites' Antigenic Variation Network Project Grant R01AI161299 worth $3,371,157 from the National Institute of Allergy and Infectious Diseases in September 2021 with work to be completed primarily in New York New York United States. The grant has a duration of 6 years and was awarded through assistance program 93.855 Allergy and Infectious Diseases Research. The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).

Status
(Ongoing)

Last Modified 8/5/26

Period of Performance
9/22/21
Start Date
8/31/27
End Date
85.0% Complete

Funding Split
$3.4M
Federal Obligation
$0.0
Non-Federal Obligation
$3.4M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01AI161299

Transaction History

Modifications to R01AI161299

Additional Detail

Award ID FAIN
R01AI161299
SAI Number
R01AI161299-2936068876
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NM00 NIH National Institute of Allergy and Infectious Diseases
Funding Office
75NM00 NIH National Institute of Allergy and Infectious Diseases
Awardee UEI
YNT8TCJH8FQ8
Awardee CAGE
1UMU6
Performance District
NY-12
Senators
Kirsten Gillibrand
Charles Schumer

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) Health research and training Grants, subsidies, and contributions (41.0) $618,539 100%
Modified: 8/5/26